氨基观察-创新药组原创出品作者 | 武月GSK又给COPD加了一把火。7月28日,恒瑞医药宣布与GSK达成了总额高达120亿美元的全球合作,核心资产PDE3/4抑制剂HRS-9821及11个创新项目一次性“打包出海”。根据协议,GSK将先向恒瑞医药支付5亿美元作为首付款,获得HRS-9821在中国大陆以外市场的全球独家权益。这笔交易,将COPD推至聚光灯下。这个曾因传统三联疗法(ICS/LAMA/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.